Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 3c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.40), $0.03 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $870 thousand versus the consensus estimate of $552.72 thousand.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• BIG3 Basketball to go public via Graf Global merger at $290 million